International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2025   Volume 15   Issue 2

When Colloids Look Like Leads: Preventing Aggregation‑Driven False Discovery in Computational and Experimental Screening of Natural Product Compounds
Download PDF


, ,
  1. Department of Colloidal Aggregation and Assay Artefacts, Faculty of Pharmacy, Mohammed V University, Rabat, Morocco.
  2. Department of False Discovery Prevention in Natural Product Screening, Faculty of Pharmacy, University of Casablanca, Casablanca, Morocco.
Citation
Vancouver
Hariri Y, Nasser H, Zahra F. When Colloids Look Like Leads: Preventing Aggregation‑Driven False Discovery in Computational and Experimental Screening of Natural Product Compounds. Int J Pharm Phytopharmacol Res. 2025;15(2):100-8. https://doi.org/10.51847/Hzib0vaI29
APA
Hariri, Y., Nasser, H., & Zahra, F. (2025). When Colloids Look Like Leads: Preventing Aggregation‑Driven False Discovery in Computational and Experimental Screening of Natural Product Compounds. International Journal of Pharmaceutical And Phytopharmacological Research, 15(2), 100-108. https://doi.org/10.51847/Hzib0vaI29
Download citation:   EndNote   RIS
Article Link:
Downloads: 28
Views: 56
Abstract

Natural products occupy chemically rich space but can also present physicochemical behaviors that complicate screening interpretation. Among these, concentration-dependent colloidal self-assembly can transform an apparently potent molecular hit into a particle-mediated assay signal. This methodological framework examines aggregation as a false-discovery mechanism that spans experimental screening, virtual prioritization, and machine-learning data construction. The analysis distinguishes molecular structure from emergent colloidal state, apparent inhibition from target-specific pharmacology, colloid formation from precipitation or low free solubility, and rejection of an unsupported mechanism from rejection of the underlying scaffold. Evidence from biochemical and cellular screening, natural-product-derived compounds, biophysical studies, aggregation-specific machine learning, assay-liability prediction, and bioactivity-data curation is integrated into a proposed falsification-first strategy. The central proposal is that aggregation liability should enter discovery before mechanistic interpretation, computational flags should modify uncertainty and the next experiment, while condition-matched physical-state measurements and orthogonal counter-screens should test whether particle formation plausibly explains activity. A predicted aggregator is therefore not automatically rejected, and an experimentally observed aggregate is not automatically biologically irrelevant. Rescue through formulation represents a separate development hypothesis that must not retroactively validate an initial target claim. The framework is intended to reduce propagation of aggregation-contaminated activity labels into ranking systems and training sets while preserving chemically unusual candidates that survive falsification. The principal limitation is that the integrated workflow has not been prospectively validated across diverse natural-product libraries, assay formats, or model domains.

Related articles:
Most viewed articles:
Naproxen in Pain and Inflammation – A Review
Vol 11 Issue 1, 2021 | Svetoslav Nikolaev Stoev
An Overview on Emulgel
Vol 9 Issue 1, 2019 | Sreevidya V.S
Volume 16
Issue 4
2026

Call for Papers
[email protected]
Issues
Associations
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0).

Copyright © 2026 International Journal of Pharmaceutical and Phytopharmacological Research
Authors retain copyright of their article if they are accepted for publication.